Literature DB >> 32568543

Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients.

Christian Ihling1, Dirk Tänzler1, Sven Hagemann2, Astrid Kehlen3, Stefan Hüttelmaier2, Christian Arlt1, Andrea Sinz1.   

Abstract

Mass spectrometry (MS) can deliver valuable diagnostic data that complement genomic information and allow us to increase our current knowledge of the COVID-19 disease caused by the SARS-CoV-2 virus. We developed a simple, MS-based method to specifically detect SARS-CoV-2 proteins from gargle solution samples of COVID-19 patients. The protocol consists of an acetone precipitation and tryptic digestion of proteins contained within the gargle solution, followed by a targeted MS analysis. Our methodology identifies unique peptides originating from SARS-CoV-2 nucleoprotein. Building on these promising initial results, faster MS protocols can now be developed as routine diagnostic tools for COVID-19 patients. Data are available via ProteomeXchange with identifier PXD019423.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; mass spectrometry; nucleoprotein

Mesh:

Substances:

Year:  2020        PMID: 32568543      PMCID: PMC7315851          DOI: 10.1021/acs.jproteome.0c00280

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


Introduction

The disease COVID-19, caused by the SARS-CoV-2 virus, was declared a pandemic by the World Health Organization on March 12, 2020[1] and has caused more than 348 000 fatalities worldwide (date: May 26, 2020). Providing novel mass-spectrometry (MS)-based diagnostic tools that complement genomic approaches is one of the major goals of the recently formed COVID-19 mass spectrometry coalition (www.covid19-msc.org).[2] On the basis of the prospective goals of this coalition, the aim of this “proof-of-principle” study is to highlight the potential of MS in identifying SARS-CoV-2 proteins, even from highly diluted samples, such as gargle solutions of COVID-19 patients.

Experimental Section

Protein Precipitation and Digestion

Gargle solutions (20 mL in 0.9% NaCl) were obtained from three patients with confirmed COVID-19 infection. All samples had been classified as SARS-CoV-2-positive by three reverse-transcription and quantitative polymerase chain reaction (RT-qPCR) analyses identifying E-, S-, and N-gene RNAs. For protein precipitation, 1 mL of acetone (−20 °C) was added to 750 μL of gargle solution and stored overnight at −20 °C. After centrifugation, the supernatant was discarded, and the pellet was dissolved in 10 μL of SMART Digest buffer (Thermo Fisher Scientific). The solution was kept at 75 °C for 10 min. Afterward, 1 μL of PNGase F (nonreducing, NEB) was added to remove protein N-glycosylations, and the sample was incubated at 50 °C for 10 min. One μg of trypsin (SMART Digest, bulk resin option, Thermo Fisher Scientific) was added to 50 μL of SMART Digest buffer (Thermo Fisher Scientific), and the solution was incubated at 70 °C for 30 min. Reduction and alkylation were performed with dithiothreitol (DTT) and iodoacetamide, respectively. Before LC/MS analysis, trifluoroacetic acid (TFA) was added to a final concentration of 0.5% (v/v).

Nano-HPLC/Nano-ESI-Orbitrap-MS/MS

LC–/MS analysis was performed on a nano-HPLC system (UltiMate RSLC 3000) coupled to an Orbitrap Fusion Tribrid mass spectrometer with nano-ESI source (Thermo Fisher Scientific). The samples were loaded onto a trapping column (Acclaim PepMap C18, 300 μm × 5 mm, 5 μm, 100 Å, Thermo Fisher Scientific) and washed for 15 min with 0.1% (v/v) TFA at a flow rate of 30 μL/min. Trapped peptides were eluted using a separation column (200 cm μPAC, C18, PharmaFluidics) that had been equilibrated with 3% B (A: 0.1% (v/v) formic acid in water; B: 0.08% (v/v) formic acid in acetonitrile). Peptides were separated with linear gradients from 3 to 10% B over 15 min, followed by 10% B to 30% B over 165 min. The column was kept at 30 °C, and the flow rate was set to 300 nL/min. Targeted MS analysis was performed based on an inclusion list of tryptic peptides from SARS-CoV-2 proteins (Table S1).[3] The inclusion list was created with MeroX using the following settings: Tryptic cleavage at Lys and Arg, maximum of two missed cleavage sites, 5–30 amino acids per peptide, fixed modification: Cys carbamidomethylated, variable modifications: Met oxidized, Asn deamidated. Charge states 2–4 were considered for masses up to 3000, whereas charge states 2–5 were considered for masses between 3000 and 4000. In case none of the target masses from the inclusion list were detected, a TOP-5s method was applied. The resolving power in MS mode was set to 120 000 at m/z 200. A parallel data acquisition strategy was employed, relying on Orbitrap-HCD (higher energy collision-induced dissociation, R = 15 000) and linear ion trap-CID (collision-induced dissociation)-MS/MS experiments. A database search (UniProt human, dated November 2019 with 20 315 entries, and SARS-CoV-2[3]) was performed with Proteome Discoverer version 2.4 (Thermo Fisher Scientific). The search was restricted to human and SARS-COV-2 proteins. Two missed tryptic cleavages were allowed, and carbamidomethylation of Cys was set as a fixed modification, whereas Met oxidation and deamidation of Asp, due to PNGase F treatment, were set as variable modifications. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE[4] partner repository with the data set identifier PXD019423 and 10.6019/PXD019423.

Results and Discussion

Protein MS analysis of the three gargle samples from COVID-19 patients revealed a vast abundance of human proteins (Tables S2, S3, and S4). Strikingly, our protocol allowed us to identify unique peptides originating from SARS-CoV-2 nucleoprotein that were identified in two out of three samples (Figure ). These results are in agreement with preceding polymerase chain reaction (PCR) analyses, exhibiting a higher viral load in the respective samples. We estimate the viral load to be on the order of 105 to 106 genome equivalents/μL gargle solution for the two samples, in which we detected SARS-CoV-2 nucleoprotein, whereas the MS-negative sample contains only ∼103 genome equivalents/μL gargle solution.
Figure 1

Sequence coverage of SARS-CoV-2 nucleoprotein in gargle samples (A, B) of two COVID-19 patients. Identified peptides are shown in green. The peptide (aa 41–61) identified in both samples is highlighted in gray.

Sequence coverage of SARS-CoV-2 nucleoprotein in gargle samples (A, B) of two COVID-19 patients. Identified peptides are shown in green. The peptide (aa 41–61) identified in both samples is highlighted in gray. A peptide originating from SARS-CoV-2 nucleoprotein, comprising the sequence RPQGLPNNTASWFTALTQHGK (amino acids 41–61, Figure ), was found in both samples, giving the first hints regarding its value for establishing an MS-based COVID-19 diagnostic method. SARS-CoV-2 nucleoprotein packages the positive-strand viral genome RNA into a helical ribonucleocapsid and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M.[3] It is also important for enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication.[3] The N-gene was found to be the most expressed viral gene,[5] which is in agreement with peptides of SARS-CoV-2 nucleoprotein being detected in our MS analysis. Clearly, further experiments are needed to test larger patient cohorts, but our findings show that SARS-CoV-2 proteins can be identified from highly diluted solutions. Our current method has the drawback of long analysis times (3 h per sample), requiring significant optimization for future high-throughput measurements of patient samples. Also, alternative MS instrumentation, such as triple–quadrupole instruments, will be required to allow the detection and quantification of a larger number of virus proteins.
Figure 2

Fragment-ion mass spectrum (HCD-MS/MS) of the 4+ charged signal of peptide RPQGLPNNTASWFTALTQHGK (amino acids 41–61) from SARS-CoV-2 nucleoprotein.

Fragment-ion mass spectrum (HCD-MS/MS) of the 4+ charged signal of peptide RPQGLPNNTASWFTALTQHGK (amino acids 41–61) from SARS-CoV-2 nucleoprotein.

Conclusions

We present a protein MS-based method to specifically detect SARS-CoV-2 virus proteins from highly diluted gargle solutions of COVID-19 patients. This straightforward method relies on an acetone precipitation of proteins, followed by a tryptic digestion and a targeted mass spectrometric analysis of SARS-CoV-2 proteins. Using this approach, we were able to identify peptides originating from SARS-CoV-2 nucleoprotein in gargle solution samples. We are planning to apply our protocol to additional sample material, such as bronchoalveolar lavage. The future goal is to provide robust, sensitive, and reliable MS-based methods as a routine diagnostic of COVID-19 patients that complement PCR-based methods.
  63 in total

Review 1.  Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19.

Authors:  Ming Hao; Dongxu Wang; Qianyun Xia; Shaoning Kan; Lu Chang; Huimin Liu; Zhijing Yang; Weiwei Liu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

2.  Proteomics-based diagnostic peptide discovery for severe fever with thrombocytopenia syndrome virus in patients.

Authors:  Sang-Yeop Lee; Hayoung Lee; Sung Ho Yun; Edmond Changkyun Park; Giwan Seo; Hye-Yeon Kim; Sangmi Jun; Nam Hoon Kim; Dongseob Tark; Ju Yeon Lee; Chang-Seop Lee; Seung Il Kim
Journal:  Clin Proteomics       Date:  2022-07-16       Impact factor: 5.000

3.  Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS-CoV-2 RNA in unamplified samples.

Authors:  Liqian Wang; Xuejun Wang; Yungen Wu; Mingquan Guo; Chenjian Gu; Changhao Dai; Derong Kong; Yao Wang; Cong Zhang; Di Qu; Chunhai Fan; Youhua Xie; Zhaoqin Zhu; Yunqi Liu; Dacheng Wei
Journal:  Nat Biomed Eng       Date:  2022-02-07       Impact factor: 29.234

4.  A rigorous evaluation of optimal peptide targets for MS-based clinical diagnostics of Coronavirus Disease 2019 (COVID-19).

Authors:  Andrew T Rajczewski; Subina Mehta; Dinh Duy An Nguyen; Björn Grüning; James E Johnson; Thomas McGowan; Timothy J Griffin; Pratik D Jagtap
Journal:  Clin Proteomics       Date:  2021-05-10       Impact factor: 5.000

5.  The COVID-19 MS Coalition-accelerating diagnostics, prognostics, and treatment.

Authors:  Weston Struwe; Edward Emmott; Melanie Bailey; Michal Sharon; Andrea Sinz; Fernando J Corrales; Kostas Thalassinos; Julian Braybrook; Clare Mills; Perdita Barran
Journal:  Lancet       Date:  2020-05-27       Impact factor: 79.321

Review 6.  Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach.

Authors:  Dharmendra Kashyap; Nidhi Varshney; Charu Sonkar; Budhadev Baral; Hem Chandra Jha
Journal:  SN Compr Clin Med       Date:  2020-11-04

Review 7.  Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update.

Authors:  Shikha Thakur; Bibekananda Sarkar; Arshad J Ansari; Akanksha Khandelwal; Anil Arya; Ramarao Poduri; Gaurav Joshi
Journal:  Food Chem Toxicol       Date:  2020-11-27       Impact factor: 6.023

8.  Proteomics and Its Application in Pandemic Diseases.

Authors:  Suman S Thakur
Journal:  J Proteome Res       Date:  2020-11-06       Impact factor: 4.466

9.  Perspective on Proteomics for Virus Detection in Clinical Samples.

Authors:  Marica Grossegesse; Felix Hartkopf; Andreas Nitsche; Lars Schaade; Joerg Doellinger; Thilo Muth
Journal:  J Proteome Res       Date:  2020-10-22       Impact factor: 4.466

10.  Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data.

Authors:  Duarte Gouveia; Lucia Grenga; Jean-Charles Gaillard; Fabrice Gallais; Laurent Bellanger; Olivier Pible; Jean Armengaud
Journal:  Proteomics       Date:  2020-06-21       Impact factor: 5.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.